Citius Oncology expands international distribution of Lymphir (denileukin diftitox-cxdl) to European Union through exclusive agreement with Uniphar

Citius Oncology Inc., the oncology-focused subsidiary of Citius Pharmaceuticals Inc. announced that it has entered into an exclusive distribution agreement with  Uniphar , a leading international healthcare services company, to support access to Lymphir (denileukin diftitox-cxdl) outside the United States. This agreement represents Citius Oncology’s third international distribution partnership and further advances the Company’s strategy to expand global access to Lymphir via established regional partners.

Under the terms of the agreement, Uniphar will serve as the exclusive distribution partner for Lymphir in designated international territories in Western and Eastern Europe through country-specific managed access programs, where permitted by local law. Uniphar will oversee market access and distribution activities in selected territories. Citius Oncology will supply finished product and provide ongoing support in accordance with the agreement.Lymphir is not approved for clinical use outside the United States and, where permitted by local law, will be provided in the territories covered by this agreement solely through country-specific managed access programs, which do not constitute marketing authorization or a commercial launch.

“This agreement with Uniphar builds on the momentum of our international expansion efforts and reflects our commitment to partnering with experienced organizations that have deep regional expertise and proven execution capabilities,” said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharmaceuticals. “As our third international distribution agreement, this partnership further strengthens our ability to responsibly expand access to LYMPHIR for patients with limited treatment options, while continuing to lay the groundwork for long-term global growth.”

“We are thrilled to partner with Citius Oncology to expand access to LYMPHIR across Europe. Uniphar is committed to connecting patients with innovative therapies, and this agreement strengthens our ability to support clinicians and improve outcomes for those living with or relapsed or refractory cutaneous T-cell lymphoma (CTCL),” stated Brian O’Shaughnessy, Chief Commercial Officer of Uniphar.